کنترل تهوع و استفراغ با دوز کم متوکلوپروماید در بیماران تحت شیمی درمانی

Nausea and vomiting have long been the most troublesome side effects of chemotherapy. This study was designed to evaluate the abinty of metoclopramide to control nausea and vomiting in a group of patients with lung non small cell carcinoma on CAP (Cyclophosphamide, Adriamycin and Cisplatin) chemotherapy protocol. 42 patients, 30 male and 12 female, ages from 40-70 years were entered in this study during a one year period, from Oct. 1994 to Nov. 1995. All patients were free from digestive, hepatic and C.N.S diseases and they were not on any tranquilizers during chemotherapy. Metoclopramide was given 10-15 minutes before and after chemotherapy as I. V bolus injection, 0.3-0.4mg/kg and continued 10 mg/q 8 hours P. O. after cessation of chemotherapy for 24-48 hours. Every single episode of nausea and vomiting during this priod were recorded and later analysed. Result: Metoclopramide was able to control nausea and vomiting in 95% of patients recieving C.A.P chemotherapy. Mark, Smyth and "Italian group for antiemetic research" in 1987, 1991 and 1995 respectively, noted 83%, 77% and 92% control of nausea and vomiting in their patients with two antiemetic agents. Conclusion: Metoclopramide with a small effective dose, lack of serious side effects and very low cost compared to newer antiemetic agents is able to control nausea and vomiting in the majority of patients on cnomotnerepy.